Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Paying $1.53bn Upfront For Zuranolone And SAGE-324
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
You may also be interested in...
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption
For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.